26801-34-3Relevant academic research and scientific papers
Cobalt-catalyzed (Z)-selective semihydrogenation of alkynes with molecular hydrogen
Chen, Caiyou,Huang, Yi,Zhang, Zongpeng,Dong, Xiu-Qin,Zhang, Xumu
, p. 4612 - 4615 (2017)
Cobalt-catalyzed highly (Z)-selective semihydrogenation of alkynes using molecular H2 was developed using commercially available and cheap cobalt precursors. A variety of (Z)-alkenes were obtained in moderate to excellent selectivities [(Z)-alkene/(E)-alkene/alkane ratio up to >99 : 1 : 1] and it was found that the readily available ethylenediamine ligand is crucial in determining the selectivity.
Catalytic asymmetric synthesis of 2,5-dihydrofurans using synergistic bifunctional Ag catalysis
Shi, Taoda,Teng, Shenghan,Gopi Krishna Reddy, Alavala,Guo, Xin,Zhang, Yueteng,Moore, Kohlson T.,Buckley, Thomas,Mason, Damian J.,Wang, Wei,Chapman, Eli,Hu, Wenhao
supporting information, p. 8737 - 8744 (2019/10/16)
We report a bifunctional Ag catalyst promoted intramolecular capture of oxonium ylides with alkynes for the enantioselective synthesis of 2,5-dihydrofurans. This represents unprecedented synergistic catalysis of a bifunctional Ag catalyst. Mechanistic studies revealed that [(R)-3,5-DM-BINAP](AgSbF6)2 (9) is likely to be the active catalytic species and that the reaction involves second order kinetics with respect to 9, suggesting that two molecules of 9 are involved in the intramolecular trapping of a Ag-associated oxonium ylide with a Ag-activated alkyne. Based on our mechanistic hypothesis, we further optimized the reaction, rendering a facile approach to 2,5-dihydrofurans in good to excellent yields in a highly chemo- and enantioselective fashion.
AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF
-
Page/Page column 86-87, (2010/04/25)
Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.
